PLXDC2 (mouse):Fc (silent) InVivoKine(tm)

AdipoGen Life Sciences

PLXDC2 (mouse):Fc (silent) InVivoKine(tm)

10

Research Use Only

1 mg/ml

>95%

InVivoKines™. Recombinant Protein. Extracellular domain of mouse PLXDC2 (aa 31-455) is fused at the C-terminus to the Fc portion of human IgG1 (LALA-PG) (Knobs-into-Holes technology) (see reference: J.B. Ridgway, et al.; Protein Eng. 9, 617 (1996)). Source: HEK 293 cells. Produced using animal component-free medium. Lyophilized. Contains PBS. Plexin domain containing 2 (PLXDC2) is a nidogen/plexin homology transmembrane protein encoded by PLXDC2. PLXDC2 is specifically expressed on the surface of macrophages but not neutrophils, T cells, or NK cells. PLXDC2 has several functions: i) in the brain, it is involved in the proliferation and differentiation of neural progenitors during the development of the nervous system; ii) in the immune system, PLXDC2 on macrophages binds to secreted PTEN (phosphatase and tensin homolog) to sequentially activate JAK2-STAT1 signaling, reprogram macrophages and drive antitumor immunity. Aberrant expression of PLXDC2 in different cancers has been reported. PLXDC2, together with its homolog PLXDC1, seems to be also the receptor for pigment epithelium-derived factor (PEDF) in endothelial cells. The protein PLXDC2 (mouse):Fc (LALA-PG)-KIH (human) (rec.) is produced by using two different vectors, one encoding for the PLXDC2 (mouse):Fc (LALA-PG) Knobs sequence (synthesizing a protein of 110kDa) and one encoding for the Fc (LALA-PG) Holes sequence (synthesizing a protein of 28kDa). Both vectors transfected into HEK293 cells produce both Fc molecules (Knobs-into-Holes technology; J.B. Ridgway, et al.; Protein Eng. 9, 617 (1996)) required for dimerization of the Fc moieties and for secretion of the final protein PLXDC2 (mouse):Fc-KIH (human) (rec.). The LALA-PG mutations inhibit binding to FcgammaRs and C1q while FcRn binding and Fc stability remain unaffected. InVivoKines™ are a new generation of recombinant fusion proteins for immunotherapeutic, preclinical and translational in vivo research, developed and manufactured by AdipoGen Life Sciences. - Plexin domain containing 2 (PLXDC2) is a nidogen/plexin homology transmembrane protein encoded by PLXDC2. PLXDC2 is specifically expressed on the surface of macrophages but not neutrophils, T cells, or NK cells. PLXDC2 has several functions: i) in the brain, it is involved in the proliferation and differentiation of neural progenitors during the development of the nervous system; ii) in the immune system, PLXDC2 on macrophages binds to secreted PTEN (phosphatase and tensin homolog) to sequentially activate JAK2-STAT1 signaling, reprogram macrophages and drive antitumor immunity. Aberrant expression of PLXDC2 in different cancers has been reported. PLXDC2, together with its homolog PLXDC1, seems to be also the receptor for pigment epithelium-derived factor (PEDF) in endothelial cells. The PLXDC2 (mouse):Fc (silent) InVivoKine™ is produced by using two different vectors, one encoding for the PLXDC2 (mouse):Fc (LALA-PG) Knobs sequence (synthesizing a protein of 110kDa) and one encoding for the Fc (LALA-PG) Holes sequence (synthesizing a protein of 28kDa). Both vectors transfected into HEK293 cells produce both Fc molecules (Knobs-into-Holes technology; J.B. Ridgway, et al.; Protein Eng. 9, 617 (1996)) required for dimerization of the Fc moieties and for secretion of the final protein PLXDC2 (mouse):Fc (silent) InVivoKine™. The LALA-PG mutations inhibit binding to FcgammaRs and C1q while FcRn binding and Fc stability remain unaffected. InVivoKines™ are a new generation of recombinant fusion proteins for immunotherapeutic, preclinical and translational in vivo research, developed and manufactured by AdipoGen Life Sciences.

-20°C,2°C to 8°C

41116100